Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous non-expanded adipose-derived stem cells (AbelZeta)
- Development stage
- Unknown
- Lead developer
- AbelZeta, Inc.
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous non-expanded adipose-derived stem cells (ADSCs) are a cell-based regenerative therapy used for the treatment of knee osteoarthritis. The therapy involves the extraction of adipose tissue from a patient via lipoaspiration, followed by minimal processing (mechanical or enzymatic) to isolate the stromal vascular fraction (SVF) containing mesenchymal stem cells, which are then injected directly into the intra-articular space of the affected joint. Unlike cultured cell products, these cells are not expanded in vitro, which reduces regulatory complexity and maintains the cells' natural microenvironment. The therapeutic effect is attributed to the cells' ability to secrete immunomodulatory factors, reduce inflammation, and potentially promote chondroprotection and tissue repair within the osteoarthritic environment.
- Other names
- autologous adipose-derived stem cellsADSCsautologous adipose-derived mesenchymal stem cellsstromal vascular fractionSVFnon-expanded adipose-derived stem cells
Beyond the preview
Go deeper on autologous non-expanded adipose-derived stem cells (AbelZeta).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous non-expanded adipose-derived stem cells (AbelZeta).